Suppr超能文献

根治性放疗后宫颈腺癌/腺鳞癌的长期预后及预后因素。

Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy.

机构信息

Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.

出版信息

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):429-36. doi: 10.1016/j.ijrobp.2010.02.009. Epub 2010 Jun 9.

Abstract

PURPOSE

To study the outcomes of patients with adenocarcinoma/adenosquamous carcinoma (AC/ASC) of the cervix primarily treated with radiotherapy (RT), identify the prognostic factors, and evaluate the efficacy of concurrent chemoradiotherapy (CCRT) or salvage surgery.

METHODS AND MATERIALS

A total of 148 patients with Stage I-IVA AC/ASC of cervix after full-course definitive RT were included. Of the 148 patients, 77% had advanced stage disease. Treatment failure was categorized as either distant or local failure. Local failure was further separated into persistent tumor or local relapse after complete remission. The effectiveness of CCRT with cisplatin and/or paclitaxel was examined, and the surgical salvage rate for local failure was reviewed.

RESULTS

The 5-year relapse-free survival rate was 68%, 38%, 49%, 30%, and 0% for those with Stage IB/IIA nonbulky, IB/IIA bulky, IIB, III, and IVA disease, respectively, and appeared inferior to that of those with squamous cell carcinoma of the cervix treated using the same RT protocol. Incomplete tumor regression after RT, a low hemoglobin level, and positive lymph node metastasis were independent poor prognostic factors for relapse-free survival. CCRT with weekly cisplatinum did not improve the outcome for our AC/ASC patients. Salvage surgery rescued 30% of patients with persistent disease.

CONCLUSION

Patients with AC/ASC of the cervix primarily treated with RT had inferior outcomes compared to those with squamous cell carcinoma. Incomplete tumor regression after RT was the most important prognostic factor for local failure. Salvage surgery for patients with persistent tumor should be encouraged for selected patients. Our results did not demonstrate a benefit of CCRT with cisplatin for this disease.

摘要

目的

研究经放疗(RT)为主治疗的宫颈腺癌/腺鳞癌(AC/ASC)患者的结局,确定预后因素,并评估同期放化疗(CCRT)或挽救性手术的疗效。

方法和材料

共纳入 148 例经全疗程根治性 RT 治疗的 I-IVA 期宫颈 AC/ASC 患者。148 例患者中,77%为晚期疾病。将治疗失败分为远处失败或局部失败。局部失败进一步分为完全缓解后持续肿瘤或局部复发。检查了顺铂和/或紫杉醇联合 CCRT 的有效性,并回顾了局部失败的手术挽救率。

结果

无肿块的 IB/IIA 期、IB/IIA 期肿块、IIB 期、III 期和 IVA 期疾病患者的 5 年无复发生存率分别为 68%、38%、49%、30%和 0%,明显低于采用相同 RT 方案治疗的宫颈鳞癌患者。RT 后肿瘤不完全消退、低血红蛋白水平和阳性淋巴结转移是无复发生存的独立不良预后因素。每周给予顺铂的 CCRT 并未改善我们的 AC/ASC 患者的结局。挽救性手术挽救了 30%持续性疾病患者。

结论

经 RT 为主治疗的宫颈 AC/ASC 患者的结局较宫颈鳞癌患者差。RT 后肿瘤不完全消退是局部失败的最重要预后因素。对于选择的患者,应鼓励对持续性肿瘤患者进行挽救性手术。我们的结果并未显示顺铂联合 CCRT 对此类疾病有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验